AU2015313827C1 - Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients - Google Patents

Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients Download PDF

Info

Publication number
AU2015313827C1
AU2015313827C1 AU2015313827A AU2015313827A AU2015313827C1 AU 2015313827 C1 AU2015313827 C1 AU 2015313827C1 AU 2015313827 A AU2015313827 A AU 2015313827A AU 2015313827 A AU2015313827 A AU 2015313827A AU 2015313827 C1 AU2015313827 C1 AU 2015313827C1
Authority
AU
Australia
Prior art keywords
ser
gly
leu
val
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015313827A
Other languages
English (en)
Other versions
AU2015313827A1 (en
AU2015313827B2 (en
Inventor
Gregory LIGOZIO
Shephard Mpofu
Hanno Richards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015313827(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2015313827A1 publication Critical patent/AU2015313827A1/en
Application granted granted Critical
Publication of AU2015313827B2 publication Critical patent/AU2015313827B2/en
Priority to AU2018201410A priority Critical patent/AU2018201410A1/en
Publication of AU2015313827C1 publication Critical patent/AU2015313827C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
AU2015313827A 2014-09-10 2015-09-08 Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients Active AU2015313827C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018201410A AU2018201410A1 (en) 2014-09-10 2018-02-27 Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
US62/048,512 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201410A Division AU2018201410A1 (en) 2014-09-10 2018-02-27 Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (3)

Publication Number Publication Date
AU2015313827A1 AU2015313827A1 (en) 2017-02-16
AU2015313827B2 AU2015313827B2 (en) 2018-02-15
AU2015313827C1 true AU2015313827C1 (en) 2018-08-30

Family

ID=54186247

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015313827A Active AU2015313827C1 (en) 2014-09-10 2015-09-08 Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
AU2018201410A Abandoned AU2018201410A1 (en) 2014-09-10 2018-02-27 Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018201410A Abandoned AU2018201410A1 (en) 2014-09-10 2018-02-27 Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Country Status (22)

Country Link
US (2) US11278618B2 (cg-RX-API-DMAC10.html)
EP (2) EP3191120B1 (cg-RX-API-DMAC10.html)
JP (4) JP2017528465A (cg-RX-API-DMAC10.html)
KR (3) KR20170045240A (cg-RX-API-DMAC10.html)
CN (4) CN107073110A (cg-RX-API-DMAC10.html)
AU (2) AU2015313827C1 (cg-RX-API-DMAC10.html)
BR (1) BR112017003332A2 (cg-RX-API-DMAC10.html)
CA (1) CA2960754A1 (cg-RX-API-DMAC10.html)
DK (1) DK3191120T3 (cg-RX-API-DMAC10.html)
ES (1) ES2981697T3 (cg-RX-API-DMAC10.html)
FI (1) FI3191120T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240921T1 (cg-RX-API-DMAC10.html)
HU (1) HUE067081T2 (cg-RX-API-DMAC10.html)
LT (1) LT3191120T (cg-RX-API-DMAC10.html)
MX (1) MX2017003216A (cg-RX-API-DMAC10.html)
PL (1) PL3191120T3 (cg-RX-API-DMAC10.html)
PT (1) PT3191120T (cg-RX-API-DMAC10.html)
RS (1) RS65851B1 (cg-RX-API-DMAC10.html)
RU (1) RU2697383C2 (cg-RX-API-DMAC10.html)
SI (1) SI3191120T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400285T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016038538A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
US10676522B2 (en) * 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
EP3672988A1 (en) * 2017-08-23 2020-07-01 Eli Lilly and Company Treatment of genital psoriasis
AU2018361975A1 (en) * 2017-11-02 2020-05-07 Novartis Ag Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
US20200385453A1 (en) * 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
KR102604172B1 (ko) 2019-12-05 2023-11-22 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 베체트병 또는 류마티스 관절염 예방 또는 치료용 약학조성물
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013077907A1 (en) * 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
BRPI0813262A2 (pt) 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
MX356279B (es) * 2010-10-08 2018-05-22 Novartis Ag Star Métodos para el tratamiento de soriasis usando antagonistas de il-17.
AU2011325134B2 (en) * 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
TW201307845A (zh) * 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013077907A1 (en) * 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Alice B Gottlieb ET AL, Annals of the Rheumatic Diseases, 2014, pages 1 - 8 (online) *
Alice B. Gottlieb ET AL, American Colleage of Rheumatology Meeting Abstracts, 2013, abstract: 319 *
MCINNES I ET AL, ARTHRITIS & RHEUMATISM; 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETING, vol. 63, no. Suppl. S10, 2011, page S306 *

Also Published As

Publication number Publication date
RU2017107501A3 (cg-RX-API-DMAC10.html) 2019-03-12
EP3191120B1 (en) 2024-04-10
SI3191120T1 (sl) 2024-10-30
EP4406969A3 (en) 2024-11-27
US20170281762A1 (en) 2017-10-05
RU2697383C2 (ru) 2019-08-13
FI3191120T3 (fi) 2024-07-10
AU2015313827A1 (en) 2017-02-16
JP7288927B2 (ja) 2023-06-08
JP2025024104A (ja) 2025-02-19
EP4406969A2 (en) 2024-07-31
CN113069542A (zh) 2021-07-06
RU2017107501A (ru) 2018-10-10
CN107073110A (zh) 2017-08-18
PT3191120T (pt) 2024-07-16
CN115944734A (zh) 2023-04-11
US11278618B2 (en) 2022-03-22
AU2015313827B2 (en) 2018-02-15
LT3191120T (lt) 2024-07-25
US20220313818A1 (en) 2022-10-06
KR20230170796A (ko) 2023-12-19
JP2023109973A (ja) 2023-08-08
HRP20240921T1 (hr) 2024-10-11
CN115957326A (zh) 2023-04-14
RS65851B1 (sr) 2024-09-30
ES2981697T3 (es) 2024-10-10
SMT202400285T1 (it) 2024-09-16
PL3191120T3 (pl) 2024-08-26
JP2021152021A (ja) 2021-09-30
JP7591092B2 (ja) 2024-11-27
AU2018201410A1 (en) 2018-03-22
CA2960754A1 (en) 2016-03-17
KR20260087713A (ko) 2026-06-11
WO2016038538A1 (en) 2016-03-17
KR20170045240A (ko) 2017-04-26
HUE067081T2 (hu) 2024-09-28
MX2017003216A (es) 2017-05-23
BR112017003332A2 (pt) 2017-11-28
EP3191120A1 (en) 2017-07-19
DK3191120T3 (da) 2024-07-15
JP2017528465A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
US20220313818A1 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritic patients
US20250066466A1 (en) Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
KR20140008305A (ko) Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
KR20220066318A (ko) 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
HK40110169A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 APR 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 APR 2018

FGA Letters patent sealed or granted (standard patent)